



Press Release

CRITICAL OUTCOME ADDS A CANADIAN PATENT TO COTI-2'S GROWING INTELLECTUAL PROPERTY PORTFOLIO

P53-dependent cancer treatment IP coverage extended to home market

London, Ontario (October 15, 2014): Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX Venture: COT; OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that its lead cancer drug candidate, COTI-2, has received its first Canadian patent, adding to a portfolio that includes six U.S. patents and one Japanese patent.

"This Canadian composition of matter patent follows on the heels of our recently announced sixth U.S. and first Japanese patent, further solidifying the intellectual property position surrounding our lead oncology asset," said Dr. Wayne Danter, President and CEO. "As we continue the development of COTI-2 towards a clinical trial, we are building a strong patent portfolio that will support and facilitate future commercial licensing opportunities."

Canadian Patent No. 2,673,683 covers the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, and methods of manufacturing the compounds. This subject matter has previously been covered in patents received in the U.S. and Japan.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com

Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416-500-8061
Email: trevor@heislercommunications.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.